• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
Harvard Law School Bankruptcy Roundtable

Harvard Law School Bankruptcy Roundtable

  • Blog
  • About Us
  • Coverage-in-Depth
    • Crypto-Bankruptcy
    • Purdue Pharma Bankruptcy
    • Texas Two-Step and the Future of Mass Tort Bankruptcy
  • Subscribe
  • Show Search
Hide Search

Recognition of Nonconsensual Third-Party Releases in Ch. 15 After Purdue

By George W. Shuster, Jr. (WilmerHale) and Benjamin W. Loveland (WilmerHale)

George W. Shuster, Jr. and Benjamin W. Loveland

The Supreme Court’s decision in Harrington v. Purdue Pharma, LP, 603 U.S. 204 (2024) has in many respects changed the landscape for nonconsensual third-party releases in chapter 11 cases.  But what effect, if any, has it had on the viability of such releases in chapter 15 cases? 

We explore that question in light two recent post-Purdue decisions that approved third-party releases in chapter 15 cases.  In In re Credito Real, No. 25-10208 (TMH), 2025 WL 977967 (Bankr. D. Del. Apr. 1, 2025), the Delaware bankruptcy court recognized a foreign debtor’s plan of reorganization that contained non-consensual third-party releases that had been approved by the foreign court overseeing the debtor’s insolvency proceedings.  In In re Odebrecht, No. 25-10482 (MG), 2025 WL 1156607 (Bankr. S.D.N.Y. Apr. 21, 2025), Judge Glenn of the SDNY bankruptcy court concluded that a US court in a chapter 15 proceeding can approve non-consensual third-party releases even if such releases were not included in a plan approved by the foreign court overseeing the debtor’s main insolvency proceedings. 

We discuss the paths that these courts took to arrive at their conclusions notwithstanding Purdue.  We also discuss how these decisions relate to historical chapter 15 jurisprudence concerning third-party releases, including cases like In re Metcalfe & Mansfield Alt. Inv., 421 B.R. 685, 696 (Bankr. S.D.N.Y. 2010) and Vitro S.A.B. de C.V., 701 F.3d 1031, 1044 (5th Cir. 2012).

Click here to read the full article.

Written by:
Editor
Published on:
November 11, 2025

Categories: Chapter 15, Statutory Interpretation, Third-Party ReleasesTags: Purdue Pharma, syndicated, Third-Party Releases

Primary Sidebar

Categories

Recent Posts

  • Liability Management Exercises Mature December 2, 2025
  • Outnumbered, Not Outplayed: Minority Lenders Successfully Challenge Exclusive Backstop Agreement on Equal Treatment Grounds in ConvergeOne November 25, 2025
  • Insolvency and systemic risks: The macroeconomic costs of director duties in crisis November 18, 2025

View by Subject Matter

363 sales Anthony Casey Bankruptcy Bankruptcy administration Bankruptcy Courts Bankruptcy Reform Chapter 11 Chapter 15 Claims Trading Cleary Gottlieb Comparative Law Corporate Governance COVID-19 cramdown David Skeel Derivatives DIP Financing Empirical Financial Crisis fraudulent transfer Jared A. Ellias Jevic Johnson & Johnson Jones Day Mark G. Douglas Mark Roe Mass Torts plan confirmation Priority Purdue Pharma Purdue Pharma bankruptcy restructuring Safe Harbors Schulte Roth & Zabel Sovereign Debt SPOE Stephen Lubben Structured Dismissals Supreme Court syndicated Texas Two-Step Trust Indenture Act Valuation Weil Gotshal Workouts

Footer

Harvard Law School Bankruptcy Roundtable

1563 Massachusetts Ave,
Cambridge, MA 02138
Accessibility | Digital Accessibility | Harvard Law School

Copyright © 2023 The President and Fellows of Harvard College

Copyright © 2025 · Navigation Pro on Genesis Framework · WordPress · Log in